Institut de chimie Organique et Analytique
is born in 1969 in Montreuil sur Mer, a nice small town in the north of France. He started his career with a PhD n Lille and discovered novel chemical nucleases. After a post-doctoral position with UCB pharma, he joined, as assistant professor, the Gerald Guillaumet Group in Orleans and developed novel methodologies in organic synthesis and series for medicinal chemistry and more precisely worked in heterocyclic chemistry. In 2007, he became full professor and leader of a research team (with Drs F. Buron, K. Plé and 10 students).
He has received several national funding and two Labex IRON and SYNORG grants (French excellence programs). He is the lead of integrated academic or industrial medicinal chemistry programs which are oriented in the discovery of heterocyclic drugs for innovative medicine (imaging and therapy, chemical biology). He is author of 154 publications (h index 31)and filed 12 patents. In 2019 he co-funded Starlight company which valorize one patent and an exclusive know-how in the chemical biology field for ADME-Tox studies.
Technical Skills:
Methodology : organometallic and heteroaromatic chemistry, pseudopeptidic synthesis, hemisynthesis of natural products. Novel Technologies for organic chemistry: greener process and flow chemistry.
Chemical engineering for health: hit to lead optimization, drug design (Cancer CNS pathologies, Metabolic disorders and inflammatory disease) ,
Imaging (Preparation of substrate for 11C and 18F radiolabeling).,
Chemical biology : targeted fluorescent probes, Protacs, suicide inhibitors) ,
Réferences:
Avula, S. ; Peng, X. ; Lang, X. ; Tortorella, M. ; Josselin, B. ; Bach, S. ; Bourg, S. ; Bonnet, P. ; Buron, F. ; Ruchaud, S. ; Routier, S. ; Néagoie, C.Design and biological evaluation of substituted 5,7-dihydro-6H-indolo[2,3-c]quinolin-6-one as novel selective Haspin inhibitors. J. Enzym. Inhib. Med. Chem. 2022, 37, 1632-1650.
Chaney, A. M. ; Lopez-Picon, F. R. ; Sérrière, S. ; Wang, R. ; Bochicchio, D. ; Webb, S. D. ; Vandesquille, M. ; Harte, M. K. ; Georgiadou, C. ; Lawrence, C. ; Busson, J. ; Vercouillie, J. ; Tauber, C. ; Buron, F. ; Routier, S. ; Reekie, T. ; Snellman, A. ; Kassiou, M. ; Rokka, J. ; Davies, K. E. ; Rinne, J. O. ; Salih, D. A. ; Edwards, F. A. ; Orton, L. D. ; Williams, S. R. ; Chalon, S. ; Boutin, H. TP rodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD .theranostics 2021, 11, 6644-6667.
Garnier, S. ; Brugemann, K. ; Zak, A. ; Vercouillie, J. ; Potier-Cartereaux, M. ; Marchivie, M. ; Routier, S. ; Buron, F.
A facile one-pot synthesis of new poly functionalized pyrrolotriazoles via a regioselective multicomponent cyclisation and Suzuki–Miyaura coupling reactions. Catalysts 2022, 12, 828.
Sava, A. ; Buron, F. ; Routier, S. ; Panainte, A. ; Bibire, N. ; Profire, L.New nitric oxide-releasing indomethacin derivatives with 1,3-thiazolidine-4-one scaffold: Design, synthesis, in silico and in vitro studies Biomedicine & Pharmacotherapy 2021, 139, 111678.
Elie, J. ; Feizbakhsh, O. ; Desban, N. ; Josselin, B. ; Baratte, B. ; Bescond, A. ; Duez, J. ; Fant, X. ; Bach, S. ; Marie, D. ; Place, M. ; Ben Salah, S. ; Chartier, A. ; Berteina-Raboin, S. ; Chaikuad, A. ; Knapp, S. ; Carles, F. ; Bonnet, P. ; Buron, F. ; Routier, S. ; Ruchaud, S.Design of new disubstituted imidazo[1,2-b]pyridazine derivatives as selective Haspin inhibitors. Synthesis, binding mode and anticancer biol J. Enzym. Inhib. Med. Chem. 2020, 35, 1840–1853.
Travaillons ensemble
Contactez-nous pour que nous puissions travailler ensemble.